TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
TYME Technologies announced its abstract acceptance for presentation at the 2022 ASCO Gastrointestinal Cancers Symposium in January, showcasing Oral SM-88, a therapy showing promise in treating advanced pancreatic cancer. The presentation is part of their ongoing efforts to develop cancer metabolism-based therapies (CMBTs), targeting various solid tumors and hematologic cancers. CEO Richie Cunningham expressed excitement over the selection from over 750 submissions, highlighting the significance of their research in innovative gastrointestinal cancer treatments.
- Abstract accepted for presentation at ASCO 2022, indicating recognition of research quality.
- Oral SM-88 shows potential effectiveness in treating advanced pancreatic cancer with a less toxic profile.
- Ongoing development of SM-88 demonstrates promise across multiple advanced cancers.
- None.
-- Oral SM-88 is an investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different types of solid tumors and hematologic cancers –
-- Prestigious conference features new, innovative findings in gastrointestinal cancer treatment, research and care –
“We are delighted that our abstract was chosen from among the more than 750 submissions that were reviewed by the Symposium Program Committee, and we look forward to sharing more information about this important work at the conference,” stated
Additional information on the meeting can be found on the ASCO 2022 Gastrointestinal Cancers Symposium website https://conferences.asco.org/gi/program.
Poster Presentation Details:
Abstract Number: 585
Abstract Title: Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final phase II/III study results.
Session Information: Poster Session B: Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time:
About
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.
The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.
For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. SM-88 is being evaluated in an adaptive randomized Phase 2/3 clinical trial for patients with second-line pancreatic cancer. The Company has begun enrollment in a Phase II study evaluating SM-88 in breast cancer (HR+/HER2-) in the third quarter of calendar year 2021, as well as continuing enrollment of a Phase II study in high-risk metastatic sarcomas. SM-88 is an investigational therapy that is not approved for any indication in any disease.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, , preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the COVID-19 pandemic and the associated impact on the national and global economy as well as impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new product candidates; expected releases of interim or final data from our clinical trials; possible collaborations; the timing, scope, status, objectives of our ongoing and planned trials; the success of management transitions and strategic initiatives; and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic impact of the COVID-19 pandemic; our ability to achieve the intended benefits of our strategic initiatives; that certain information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data or analyses and may not support further clinical development; and that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K for the fiscal year ended
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005216/en/
Investor Relations:
T: 212-452-2793
E: lwilson@insitecony.com
Source:
FAQ
What is the significance of TYME Technologies' abstract accepted at the ASCO 2022?
When will TYME Technologies present its findings on Oral SM-88?
What is Oral SM-88 and how does it work?
What types of cancer is SM-88 being evaluated for?
What does CMBTs stand for in the context of TYME Technologies?
